Clinical Trials Sponsored by Zymenex A/S

Total 2501 results

Coloplast A/S

Completed

Investigation of a New 1-piece Convex Ostomy Product

Stoma Ileostomy | Stoma Colostomy

Denmark
Coloplast A/S

Completed

An Exploratory Study Investigating Adhesive Reaction to Output

Ileostomy

Denmark
Coloplast A/S

Completed

Investigation of Newly Developed Ostomy Products in Subjects With Ileostomy

Stoma Ileostomy

France, Denmark, United Kingdom, Germany, Norway
Coloplast A/S

Terminated

Exair® Versus Native Tissue Repair for Prolapse

Pelvic Organ Prolapse

United States, Canada
Pharmacosmos A/S

Completed

A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Non-myeloid Malignancies | Chemotherapy Induced Anaemia

India
Pharmacosmos A/S

Completed

A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With IV Iron Sucrose in Subjects With CKD-5D

Chronic Kidney Disease Stage 5 (Dialysis Dependent)

India
Coloplast A/S

Unknown

Quality of Life in Patients With Double Loop Ureteral Stent (JJ Silicone Hydrogel Study)

Kidney Calculi

France
Origio A/S

Completed

Efficacy Study of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) for Use in Human IVF (GM-CSF)

Infertility

Denmark, Sweden
Pharmacosmos A/S

Completed

Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease (IBD-02)

Inflammatory Bowel Disease

Denmark
Coloplast A/S

Terminated

Multi-national, Safety and Performance Study of New Ostomy Product Compared to Standard Care

Skin Condition | Leakage

Denmark, France, Germany, Iceland
Coloplast A/S

Completed

An Investigation of Ostomy Devices

Ileostomy

Denmark
Coloplast A/S

Completed

Investigation of Newly Developed 1-piece Convex Baseplates in Subjects With Ileostomy

Ileostomy - Stoma

Netherlands
Coloplast A/S

Completed

Human Skin Test Model in Colostomists

Colostomy Stoma
Coloplast A/S

Completed

A Clinical Investigation of New Ostomy Appliances

Leakage

Denmark
Coloplast A/S

Completed

Bladder Scan of Residual Urine With New Catheter

Urinary Incontinence

Germany
CytoVac A/S

Completed

Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy (ALECSAT)

Hormone-refractory Prostate Cancer

Denmark
Coloplast A/S

Completed

Test of Discomfort and Malaise of Two Different Urine Catheters in Healthy Volunteers

Spinal Cord Injury

Denmark
Coloplast A/S

Completed

Physiotulle vs Urgotul in the Treatment of Leg Ulcer

Leg Ulcers

France, Denmark
NatImmune A/S

Unknown

bLAC - Treatment of Cutaneous Warts in Immune Suppressed, Kidney Transplanted Patients

Cutaneous Warts

Denmark
NeuroSearch A/S

Completed

Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

United States
Ascendis Pharma Oncology Division A/S

Recruiting

TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (BelieveIT-201)

Head and Neck Neoplasms

United States, Spain, Georgia, Hungary, Germany, Italy, Taiwan
Ascendis Pharma Endocrinology Division A/S

Recruiting

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA (SkybriGHt)

Growth Hormone Deficiency

United States
Ascendis Pharma Endocrinology Division A/S

Recruiting

A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin (SkyPASS)

Growth Hormone Deficiency

United States
Ascendis Pharma Endocrinology Division A/S

Active, not recruiting

A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

Turner Syndrome

United States
Ascendis Pharma Growth Disorders A/S

Active, not recruiting

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia (ApproaCH)

Achondroplasia

United States, Denmark, Ireland, New Zealand, Australia, Canada, Spain
Ascendis Pharma Endocrinology Division A/S

Active, not recruiting

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Endocrine System Diseases | Adult Growth Hormone Deficiency | Hormone Deficiency

United States, Armenia, Georgia, Greece, Ukraine, Australia, Canada, France, Israel, Italy, Japan, Malaysia, Poland, Romania, Serbia, Slovakia, Spain, Turkey, United Kingdom, Germany, Korea, Republic of
Ascendis Pharma Endocrinology Division A/S

Completed

A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency

Endocrine System Diseases | Pituitary Diseases | Hormone Deficiency | Growth Hormone Deficiency, Pediatric

United States, Canada, Australia, New Zealand
Ascendis Pharma Growth Disorders A/S

Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia

Achondroplasia

United States, Australia
Ascendis Pharma Oncology Division A/S

Recruiting

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor | Locally Advanced Solid Tumor | Neoadjuvant Melanoma | Head and Neck Squamous Cell Carcinoma HNSCC | HPV-associated Cancers | Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)

United States, Australia, Spain, Netherlands, Korea, Republic of, Taiwan
Ascendis Pharma Growth Disorders A/S

Enrolling by invitation

A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia (AttaCH)

Achondroplasia

United States, Australia, Denmark, Ireland, Austria, Germany, New Zealand
Ascendis Pharma Endocrinology Division A/S

Completed

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency (foresiGHt)

Endocrine System Diseases | Growth Hormone Deficiency | Hormone Deficiency

United States, Armenia, Georgia, Turkey, Ukraine, Australia, Canada, Denmark, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, New Zealand, Poland, Romania, Serbia, Slovakia, Spain, United Kingdom
Novo Nordisk A/S

Not yet recruiting

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Alcohol-related Liver Disease

Spain, Denmark, United States, Australia, Canada, Netherlands, Italy, Bulgaria, Czechia, Germany, Greece, France, Japan, Poland
Novo Nordisk A/S

Not yet recruiting

Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Recruiting

A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Recruiting

A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People

Healthy Volunteers | Cardiometabolic Diseases

Netherlands
Novo Nordisk A/S

Recruiting

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise (REIMAGINE 1)

Type 2 Diabetes

United States, Serbia, Italy, Poland, China, Hungary, Saudi Arabia
H. Lundbeck A/S

Recruiting

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments (PROCEED)

Migraine

United States
Novo Nordisk A/S

Not yet recruiting

Special Use - Results Surveillance on Long-term Use With Wegovy®

Obesity

Japan
Novo Nordisk A/S

Recruiting

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

United States, Netherlands, Germany, Canada, Czechia, France, Italy, Portugal, Spain
Novo Nordisk A/S

Recruiting

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Type 2 Diabetes

United States, Taiwan, Australia, Hungary, Germany, India, Canada, Spain, Czechia, Argentina, Poland, Colombia, South Africa, France, Greece, Romania
Novo Nordisk A/S

Recruiting

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation (ATHENA)

Heart Failure | Systemic Inflammation

United States, Greece, France, Australia, Czechia, Spain, India, Canada, Turkey, Portugal, Malaysia, Poland, United Kingdom, Germany, Bulgaria, Argentina
Novo Nordisk A/S

Recruiting

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

Obesity

United States
Novo Nordisk A/S

Recruiting

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

Obesity | Type 2 Diabetes | Chronic Kidney Disease

United States, Spain, Poland, Thailand, India, France, Argentina, Canada, Japan, Greece, Hungary, Brazil, Slovakia
Novo Nordisk A/S

Not yet recruiting

A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes

Diabetes Mellitus, Type 2

Italy
Novo Nordisk A/S

Recruiting

Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants

Healthy Participants

Germany
Novo Nordisk A/S

Recruiting

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (REIMAGINE 2)

Type 2 Diabetes Mellitus

Korea, Republic of, United States, Serbia, Hungary, Spain, China, Australia, Finland, United Kingdom, Italy, Denmark, Canada, Taiwan, Germany, Sweden, South Africa, India, Poland, Argentina, Brazil, Bulgaria, Japan, Mexico, Turkey, Greece, Colomb... and more
Novo Nordisk A/S

Recruiting

A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range (STEP12)

Obesity | Overweight

China, Taiwan
Novo Nordisk A/S

Recruiting

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Healthy Volunteers | Dyslipidaemia

United States
H. Lundbeck A/S

Recruiting

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine (PROSPECT-1)

Episodic Migraine

Spain, Italy, Portugal, United States, Canada, United Kingdom, Argentina
Novo Nordisk A/S

Recruiting

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight (STEP Young)

Obesity

Belgium, United Kingdom, Denmark, United States, Sweden, Portugal, Austria, Germany, Israel, Mexico

Clinical Trials Sponsored by Zymenex A/S

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations